Study of plasma-derived miRNAs mimic differences in Huntington's disease brain.

Biomarkers for Huntington’s disease (HD) progression could accelerate therapeutic developments and improve patient care. Brain microRNAs (miRNA) relating to clinical features of HD may represent a potential HD biomarker in blood. Examine candidate miRNAs in plasma to determine if changes observed in HD brains are detectable in peripheral samples. Four miRNA from 26 manifest HD, 4 asymptomatic HD gene carriers and 8 controls were quantified in plasma using RT-qPCR. Linear regression was used to assess miRNA levels across control, asymptomatic gene carriers and manifest patients. miR-10b-5p (p= 0.0068) and miR-486-5p (p= 0.044) were elevated in HD plasma. miR-10b-5p was decreased in asymptomatic gene carriers as compared to HD patients (p= 0.049), but no difference between asymptomatic gene carriers and controls was observed (p= 0.24). These findings suggest miRNA changes observed in HD brain may be detectable in plasma and have potential clinical utility.

亨廷顿病（HD）进展的生物标志物可以加速治疗发展并改善患者护理。与HD临床特征相关的脑微小核糖核酸（miRNA）可能是血液中一种潜在的HD生物标志物。 检测血浆中的候选miRNA，以确定在HD大脑中观察到的变化是否能在外周样本中检测到。 使用逆转录定量聚合酶链反应（RT - qPCR）对26例显性HD患者、4例无症状HD基因携带者和8例对照者的血浆中的4种miRNA进行定量。采用线性回归评估对照组、无症状基因携带者和显性患者之间的miRNA水平。 miR - 10b - 5p（p = 0.0068）和miR - 486 - 5p（p = 0.044）在HD血浆中升高。与HD患者相比，无症状基因携带者中miR - 10b - 5p降低（p = 0.049），但无症状基因携带者和对照组之间未观察到差异（p = 0.24）。 这些发现表明，在HD大脑中观察到的miRNA变化可能在血浆中可检测到，并具有潜在的临床应用价值。